1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Sichuan Kelun Pharmaceutical Co., Ltd.
  6. Summary
    002422   CNE100000PW7

SICHUAN KELUN PHARMACEUTICAL CO., LTD.

(002422)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
17.94 18.32 17.95 17.78 17.73 Last
11292310 13743360 31595250 17498390 10368370 Volume
+0.45% +2.12% -2.02% -0.95% -0.28% Change
Estimated financial data (e)
Sales 2022 18 841 M 2 790 M 2 790 M
Net income 2022 1 342 M 199 M 199 M
Net Debt 2022 9 928 M 1 470 M 1 470 M
P/E ratio 2022 18,8x
Yield 2022 1,75%
Sales 2023 21 060 M 3 118 M 3 118 M
Net income 2023 1 547 M 229 M 229 M
Net Debt 2023 9 429 M 1 396 M 1 396 M
P/E ratio 2023 16,4x
Yield 2023 2,41%
Capitalization 24 933 M 3 692 M 3 692 M
EV / Sales 2022 1,85x
EV / Sales 2023 1,63x
Nbr of Employees 19 031
Free-Float 57,4%
More Financials
Company
Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows: - manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.); - other (2%). China accounts for 94.6% of net sales. 
Sector
Pharmaceuticals
Calendar
08/31Earnings Release
More about the company
Ratings of Sichuan Kelun Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SICHUAN KELUN PHARMACEUTICAL CO., LTD.
05/17Kelun Pharma Licenses Cancer Drug to Merck Unit For Up to $1.4 Billion
MT
05/09Sichuan Kelun Pharmaceutical Co., Ltd. Announces Final Distribution for the Year 2021, ..
CI
05/06Sichuan Kelun Pharmaceutical Co., Ltd. Approves Dividend for 2021
CI
04/26Sichuan Kelun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million ..
CI
04/26Sichuan Kelun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
04/18Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter E..
CI
04/12Tranche Update on Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announce..
CI
04/12Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 30, 2021, has..
CI
04/11Kelun Pharmaceutical Lifts Final Dividend as 2021 Profit Jumps 33%
MT
04/11Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021
CI
03/16Sichuan Kelun Pharmaceutical to Sell $472 Million RMB Convertible Bonds
MT
02/22Chinese Regulators OK HBM's Investigational New Drug Application for Asthma Treatment; ..
MT
01/19Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 21, 2021, ..
CI
01/07Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended..
CI
01/05Tranche Update on Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announce..
CI
More news
News in other languages on SICHUAN KELUN PHARMACEUTICAL CO., LTD.
05/17Kelun Pharma accorde une licence pour un médicament contre le cancer à une unité de Mer..
05/09Sichuan Kelun Pharmaceutical Co., Ltd. annonce la distribution finale pour l'année 2021..
05/06Sichuan Kelun Pharmaceutical Co., Ltd. approuve le dividende pour 2021
04/26SICHUAN KELUN PHARMACEUTICAL CO., LT : 002422) annonce un rachat d'actions pour une valeur..
04/26Sichuan Kelun Pharmaceutical Co., Ltd. autorise un plan de rachat.
More news
Chart SICHUAN KELUN PHARMACEUTICAL CO., LTD.
Duration : Period :
Sichuan Kelun Pharmaceutical Co., Ltd. Technical Analysis Chart | 002422 | CNE100000PW7 | MarketScreener
Technical analysis trends SICHUAN KELUN PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 17,73 CNY
Average target price 20,28 CNY
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Si Chuan Liu Director & Deputy General Manager
De Gui Lai Chief Financial & Accounting Officer, Deputy GM
Ge Xin Liu Chairman
Peng Wan Legal Affairs Director
Yue Dong Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SICHUAN KELUN PHARMACEUTICAL CO., LTD.-6.34%3 711
JOHNSON & JOHNSON2.59%470 547
PFIZER, INC.-14.65%288 063
ABBVIE INC.12.58%273 513
ELI LILLY AND COMPANY6.87%271 308
ROCHE HOLDING AG-14.97%263 868